P2.11B.05 Effect of Dysbiosis-Inducing Drugs on the Response to Immune Checkpoint Inhibitors in Patients with NSCLC von Lopes, S., Bertrand, B., Lucile, P., Creusot, Q., Mennecier, B., Pamart, G., Matau, C., Pancreach, E., Beau-Faller, M., Dory, A., Mascaux, C.

Volltext

EP07.04-01 Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results von Pasini, L., Petracci, E., Urbini, M., Felip, E., Stella, F., Tebaldi, M., Azzali, I., Martinez-Marti, A., Pancreach, E., Davoli, F., Salvi, M., Beau, M., Solli, P., Lai, G., Amat, R., Carbonell, C., Delmonte, A., Crinò, L., Ulivi, P.

Volltext